Max Rosett joined Morphimmune as Acting COO in 2022. Prior to joining Morphimmune, Mr. Rosett served as a Principal at Research Bridge Partners, where he led the Morphimmune Series A. He has over a decade of experience in data-driven roles, including time working in business operations at a Silicon Valley startup and as an engineer at Google. He started his career at the Boston Consulting Group, where he served clients in the pharmaceutical industry. Mr. Rosett holds an MS from Georgia Tech and a BA in math from Yale.